珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
2023年09月26日 19:10:02来源:作者:

Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution]
CUVITRU is Takeda’s First Subcutaneous Immunoglobulin Plasma Therapy in Japan, Delivering on the Company’s Commitment to Reach Patients with High Unmet Needs

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAKtoday announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks Takeda’s first subcutaneous immunoglobulin (SCIG) therapy for patients in Japan.

The approval is based on results from a Phase 3 clinical trial that evaluated the efficacy, safety, tolerability and pharmacokinetics of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in Japanese patients with PID (NCT04346108), as well as two Phase 2/3 clinical trials conducted in patients with PID in North America (NCT01218438) and Europe (NCT01412385). Results from the clinical trial in 17 patients in Japan confirmed its efficacy and safety profile1. No serious or severe adverse events were reported, and CUVITRU was well-tolerated. The most frequently reported adverse reactions were injection site swelling in four patients (23.5%) and injection site erythema in three patients (17.6%)1 during CUVITRU treatment. Previously reported clinical trial results also confirmed the efficacy and safety of CUVITRU.

“We are delighted that CUVITRU, approved in more than 30 countries worldwide, has now been approved in Japan as our first subcutaneous immunoglobulin treatment for agammaglobulinemia or hypogammaglobulinemia,” said Naoyoshi Hirota, regional head of research & development for Takeda’s Plasma-Derived Therapies Business Unit in Japan. “Patients with immunodeficiency often contract serious infections, including pneumonia, sepsis and other recurring infections. Immunoglobulin replacement therapy is the standard of care, and we are proud to offer a new flexible dosing regimen to patients in Japan.”

Timely diagnosis of PID is problematic in Japan and treatment with immunoglobulins is currently much lower than in other parts of the world3,4. Patient demand for plasma-derived therapies (PDTs) is expected to grow significantly in the coming years, and Takeda is leading regulatory efforts and discussions to elevate the standard of care in Japan and introduce more of Takeda’s PDT portfolio into the country.

“Takeda is proud to build on our long and rich Japanese heritage by continuing to invest in and expand our PDT offerings to address the needs of patients,” said Kristina Allikmets, head of research & development for Takeda’s Plasma-Derived Therapies Business Unit. “Hand in hand with our recent investment in an end-to-end global plasma manufacturing facility in Osaka, the approval of CUVITRU marks the start of our commitment to bringing our broad and differentiated global PDT portfolio to immunodeficient patients in Japan over the next decade.”

About Agammaglobulinemia or Hypogammaglobulinemia
Agammaglobulinemia is an inherited disorder caused by a gene defect that blocks the growth of normal, mature immune cells called B lymphocytes, and produces antibodies5. Hypogammaglobulinemia describes a condition in which patients have low levels of antibodies and can be both due to inherited genetic conditions, or caused by secondary effects, such as chemotherapy, certain comorbid disorders, or the use of immunosuppressants2. Individuals with any form of antibody deficiency frequently experience recurring infections, and immunoglobulin replacement therapy can increase the level of antibodies in the body.

About Primary Immunodeficiency and Secondary Immunodeficiency
Primary immunodeficiency (PID) describes a heterogenous group of more than 480 rare genetic diseases wherein part of the immune system is missing or not functioning properly6. Secondary immunodeficiency (SID) may be defined as an impairment of the immune response resulting from conditions or factors extrinsic to the immune system. SID may occur as a consequence of malnutrition, metabolic disorders, use of immunosuppressive medications, chronic infections, malignancies, or severe trauma7. Due to their impaired immune system, patients with PID and SID may be more susceptible to infection and it may take longer to recover from it. In patients with antibody deficiency and increased susceptibility and/or persistent infections, substitution with functional antibodies (immunoglobulin replacement therapy) is the standard of care to support the immune system's functioning7.

About CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution]
CUVITRU is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Solution indicated in Japan as a treatment for agammaglobulinemia or hypogammaglobulinemia in patients aged 2 years and older. It was developed as a treatment to help prevent infection in adult and pediatric patients with PID or SID. As of May 2022, it has been approved in over 30 countries.

CUVITRU Product Overview in Japan

Brand Name

CUVITRU 20% S.C. Infusion 2 g/10 mL, 4 g/20 mL, 8 g/40 mL

Generic Name

pH4-Treated Acidic Normal Human Immunoglobulin (Subcutaneous injection)

Indications

Agammaglobulinemia or Hypogammaglobulinemia

Dosage and

Administration

 

Normally, 50 ~ 200 mg (0.25 ~ 1 mL)/kg body weight of human immunoglobulin G is administered subcutaneously once a week. In case of every 2 weeks regimen, 2-fold higher dose than once-a-week regimen (100 ~ 400 mg [0.5 ~ 2 mL]/kg body weight) will be administered subcutaneously. The dose and dosing frequency of once-a-week or every-2-weeks regimen may be adjusted according to the patient's condition.

 

责任编辑: admin

看新闻,关注新闻

天涯网友:冷笑你的无知
评论:所谓大学:管理监狱化 素质流氓化 kiss公开化 消费白领化 上课梦境化 逃课普遍化 寝室网吧化

搜狐网友:余存° d3sTiny-
评论:结婚的日子我已经定好了,现在就差定新郎了。

天猫网友:㎜  安然失笑
评论:生活就像新闻联播,不是换台就能逃避的了。

其它网友:惆怅 ▍ Burlk
评论:人生就是这样:不是你混日子;就是日子把自己混了

凤凰网友:离岛║Bombastic Love
评论:您好:把您闺女借我一年,明年还您一大一小。

百度网友:Mo Maek 莫陌
评论:你打扮成这样,是对这个世界有什么不满吗?

淘宝网友:你真叫我作呕
评论:我们这个年龄,更多的是练爱而不是恋爱。

腾讯网友:Flowers ( 繁花 )
评论:终于知道为什么军训要左右转动了,因为这样晒得均匀。

猫扑网友:红玫瑰‖▍DAEGER
评论:我知道强扭的瓜不甜,但是本人就是不喜欢吃甜瓜。

网易网友:疲惫了放手了
评论:世界上最动听的话不是我爱你,而是你的肿瘤是良性的!

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!